## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%); PEG 4.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($654.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Friedenthal Financial Buys New Stake in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251224T100434 | Bullish | Relevance: 100%
- Friedenthal Financial has acquired a new stake of 1,657 shares in IDEXX Laboratories, Inc., valued at approximately $1,059,000 during the third quarter. This investment comes as several other institutional investors have also adjusted their holdings in the animal health diagnostics company, which currently holds a "Moderate Buy" rating from analysts with a consensus price target of $763.50. IDEXX Laboratories recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue.

**2. Swedbank AB Purchases 2,107 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251227T104920 | Somewhat-Bullish | Relevance: 100%
- Swedbank AB increased its stake in IDEXX Laboratories, Inc. by 5.9%, acquiring an additional 2,107 shares in the third quarter, bringing its total holdings to 37,832 shares valued at approximately $24.17 million. Meanwhile, IDEXX EVP Nimrata Hunt sold 9,425 shares, reducing her position by over 30%. Analysts maintain a "Moderate Buy" rating for IDEXX, with a consensus target price of $763.50, following strong Q3 earnings and positive FY2025 guidance.

**3. IDEXX Laboratories, Inc. $IDXX Shares Acquired by Beacon Investment Advisory Services Inc.**
- Source: MarketBeat | 20251227T080752 | Bullish | Relevance: 100%
- Beacon Investment Advisory Services Inc. increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 15.7% in the third quarter, now owning 56,241 shares valued at $35.93 million. This makes IDEXX its 16th largest position, representing about 0.07% of the company's outstanding stock. IDEXX recently beat quarterly earnings expectations, and analysts have set a "Moderate Buy" consensus rating with an average target price of $763.50.

**4. BankPlus Trust Department Purchases 1,830 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251228T080819 | Bullish | Relevance: 100%
- BankPlus Trust Department significantly increased its stake in IDEXX Laboratories, purchasing 1,830 additional shares to bring its total holdings to 1,962 shares, valued at approximately $1.254 million. The company recently exceeded Q3 earnings expectations, reporting an EPS of $3.22 and revenue of $1.11 billion, leading to several analysts raising their price targets and a consensus "Moderate Buy" rating. Despite bullish institutional activity, an EVP recently sold a substantial portion of her shares, reducing her position by over 30%.

**5. Vontobel Holding Ltd. Has $94.16 Million Position in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251224T142738 | Bullish | Relevance: 99%
- Vontobel Holding Ltd. significantly reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 64.4% in the third quarter, retaining shares worth $94.16 million. IDEXX reported strong Q3 earnings, beating expectations with impressive revenue growth and providing positive FY2025 guidance. The company holds a "Moderate Buy" consensus rating from analysts, who anticipate continued growth for the animal healthcare provider.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.1x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.06 signals overvaluation risk, limited margin of safety. Forward P/E 47.8x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.1B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.06 |
| Forward P/E | 47.8 |
| Current P/E | 53.4 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.2% to -2.4% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.84), momentum weakening. RSI neutral at 44. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.40% (CS: 17) | Weak |
| RSI_14 | 44.1 | Neutral |
| MACD Histogram | -3.84 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.192x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $688.48
- **Stop Loss:** $654.68 (4.9% risk)
- **Target:** $722.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $26,850.72
- **Portfolio %:** 26.85%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*